Angptl3 Protein Inhibitors Pipeline Insight

DelveInsight’s, “ANGPTL3 Protein Inhibitors - Pipeline Insight, 2023,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in ANGPTL3 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

ANGPTL3 Protein Inhibitors Understanding

ANGPTL3 Protein Inhibitors: Overview

Angiopoietin like protein 3 (ANGPTL3) is best known for its function as an inhibitor of lipoprotein and endothelial lipases. Due to the capacity of genetic or pharmacologic ANGPTL3 suppression to markedly reduce circulating lipoproteins, and the documented cardioprotection upon such suppression, ANGPTL3 has become an emerging therapy target for which both antibody and antisense oligonucleotide (ASO) therapeutics are being clinically tested. While the antibody is relatively selective for circulating ANGPTL3, the ASO also depletes the intra-hepatocellular protein, and there is emerging evidence for cell-autonomous functions of ANGPTL3 in the liver. These include regulation of hepatocyte glucose and fatty acid uptake, insulin sensitivity, LDL/VLDL remnant uptake, VLDL assembly/secretion, polyunsaturated fatty acid (PUFA) and PUFA-derived lipid mediator content, and gene expression.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence ANGPTL3 Protein Inhibitors R&D. The therapies under development are focused on novel approaches for ANGPTL3 Protein Inhibitors.

ANGPTL3 Protein Inhibitors Emerging Drugs Chapters

This segment of the ANGPTL3 Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

ANGPTL3 Protein Inhibitors Emerging Drugs

Vupanorsen: Ionis Pharmaceuticals

Vupanorsen, formerly known as IONIS-ANGPTL3-LRx and AKCEA-ANGPTL3-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce angiopoietin-like 3 protein, or ANGPTL3. Human genetic studies have shown that lower levels of ANGPTL3 are associated with lower plasma triglyceride (TG) and LDL-C and protection against certain cardiovascular diseases. Studies in animals have demonstrated that targeted reduction of ANGPTL3 with antisense drugs results in substantially decreased TG and LDL-C2. A large number of patients with elevated risk of cardiovascular disease are not reaching recommended TG and LDL-C goals. Vupanorsen is being developed to reduce plasma levels of ANGPTL3 with the goal of lowering levels of plasma TG and LDL-C to potentially reduce the risk of future.

ARO-ANG3: Arrowhead Pharmaceuticals

ARO-ANG3 is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease.

Further product details are provided in the report……..

ANGPTL3 Protein Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different ANGPTL3 Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on ANGPTL3 Protein Inhibitors

There are approx. 4+ key companies which are developing the ANGPTL3 Protein Inhibitors. The companies which have their ANGPTL3 Protein Inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Ionis Pharmaceuticals.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

ANGPTL3 Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

ANGPTL3 Protein Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ANGPTL3 Protein Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ANGPTL3 Protein Inhibitors drugs.

ANGPTL3 Protein Inhibitors Report Insights

• ANGPTL3 Protein Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

ANGPTL3 Protein Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing ANGPTL3 Protein Inhibitors drugs?
• How many ANGPTL3 Protein Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ANGPTL3 Protein Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ANGPTL3 Protein Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for ANGPTL3 Protein Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?